BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31004012)

  • 21. Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses.
    Kapczynski DR; Pantin-Jackwood MJ; Spackman E; Chrzastek K; Suarez DL; Swayne DE
    Vaccine; 2017 Nov; 35(46):6345-6353. PubMed ID: 28456525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Protective properties of candidate genetically engineered vaccines against avian influenza viruses constructed on the basis of recombinant adenoviral vectors].
    Sedova ES; Shmarov MM; Tutykhina IL; Barykova IuA; Verkhovskaia LV; Logunov DIu; Naroditskiĭ BS; Gintsburg AL
    Zh Mikrobiol Epidemiol Immunobiol; 2010; (3):44-8. PubMed ID: 20734718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
    Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral priming with replicating adenovirus serotype 4 followed by subunit H5N1 vaccine boost promotes antibody affinity maturation and expands H5N1 cross-clade neutralization.
    Khurana S; Coyle EM; Manischewitz J; King LR; Ishioka G; Alexander J; Smith J; Gurwith M; Golding H
    PLoS One; 2015; 10(1):e0115476. PubMed ID: 25629161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of a Recombinant Turkey Herpesvirus H5 Vaccine Against Challenge With H5N1 Clades 1.1.2 and 2.3.2.1 Highly Pathogenic Avian Influenza Viruses in Domestic Ducks (Anas platyrhynchos domesticus).
    Pantin-Jackwood MJ; Kapczynski DR; DeJesus E; Costa-Hurtado M; Dauphin G; Tripodi A; Dunn JR; Swayne DE
    Avian Dis; 2016 Mar; 60(1):22-32. PubMed ID: 26953940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial.
    Treanor JJ; Chu L; Essink B; Muse D; El Sahly HM; Izikson R; Goldenthal KL; Patriarca P; Dunkle LM
    Vaccine; 2017 Feb; 35(6):923-928. PubMed ID: 28089141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.
    Sun X; Belser JA; Pulit-Penaloza JA; Creager HM; Guo Z; Jefferson SN; Liu F; York IA; Stevens J; Maines TR; Jernigan DB; Katz JM; Levine MZ; Tumpey TM
    Virology; 2017 Aug; 508():164-169. PubMed ID: 28554058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Replicating Single-Cycle Adenovirus Vectors Generate Amplified Influenza Vaccine Responses.
    Crosby CM; Matchett WE; Anguiano-Zarate SS; Parks CA; Weaver EA; Pease LR; Webby RJ; Barry MA
    J Virol; 2017 Jan; 91(2):. PubMed ID: 27807231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection.
    Asahi-Ozaki Y; Itamura S; Ichinohe T; Strong P; Tamura S; Takahashi H; Sawa H; Moriyama M; Tashiro M; Sata T; Kurata T; Hasegawa H
    Microbes Infect; 2006 Oct; 8(12-13):2706-14. PubMed ID: 16968669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Study on immunogenicity of a recombinant adenovirus vaccine containing neuraminidase gene of H5N1 influenza virus (A/Anhui/1/2005) in mice].
    Ma J; Zhang XG; Li KB; Zhang XM; Wang M; Bai T; Yang L; Xu H; Shu YL; Zeng Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Dec; 23(6):449-51. PubMed ID: 20718353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus.
    Kapczynski DR; Esaki M; Dorsey KM; Jiang H; Jackwood M; Moraes M; Gardin Y
    Vaccine; 2015 Feb; 33(9):1197-205. PubMed ID: 25613723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy.
    Kim SM; Kim YI; Park SJ; Kim EH; Kwon HI; Si YJ; Lee IW; Song MS; Choi YK
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28077631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks.
    Qian C; Chen S; Ding P; Chai M; Xu C; Gan J; Peng D; Liu X
    Vaccine; 2012 Sep; 30(44):6279-86. PubMed ID: 22902682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Purification and immunogenicity of hemagglutinin from highly pathogenic avian influenza virus H5N1 expressed in Nicotiana benthamiana.
    Pua TL; Chan XY; Loh HS; Omar AR; Yusibov V; Musiychuk K; Hall AC; Coffin MV; Shoji Y; Chichester JA; Bi H; Streatfield SJ
    Hum Vaccin Immunother; 2017 Feb; 13(2):306-313. PubMed ID: 27929750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunoprotection against influenza H5N1 virus by oral administration of enteric-coated recombinant Lactococcus lactis mini-capsules.
    Lei H; Xu Y; Chen J; Wei X; Lam DM
    Virology; 2010 Nov; 407(2):319-24. PubMed ID: 20850860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coadministration of Recombinant Adenovirus Expressing GM-CSF with Inactivated H5N1 Avian Influenza Vaccine Increased the Immune Responses and Protective Efficacy Against a Wild Bird Source of H5N1 Challenge.
    Wang X; Wang X; Jia Y; Wang C; Tang Q; Han Q; Xiao S; Yang Z
    J Interferon Cytokine Res; 2017 Oct; 37(10):467-473. PubMed ID: 29028432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progress on adenovirus-vectored universal influenza vaccines.
    Xiang K; Ying G; Yan Z; Shanshan Y; Lei Z; Hongjun L; Maosheng S
    Hum Vaccin Immunother; 2015; 11(5):1209-22. PubMed ID: 25876176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The highly conserved HA2 protein of the influenza A virus induces a cross protective immune response.
    Lee JS; Chowdhury MY; Moon HJ; Choi YK; Talactac MR; Kim JH; Park ME; Son HY; Shin KS; Kim CJ
    J Virol Methods; 2013 Dec; 194(1-2):280-8. PubMed ID: 24004822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Addition of N-glycosylation sites on the globular head of the H5 hemagglutinin induces the escape of highly pathogenic avian influenza A H5N1 viruses from vaccine-induced immunity.
    Hervé PL; Lorin V; Jouvion G; Da Costa B; Escriou N
    Virology; 2015 Dec; 486():134-45. PubMed ID: 26433051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protective immunity elicited by a pseudotyped baculovirus-mediated bivalent H5N1 influenza vaccine.
    Wu Q; Xiao S; Fan H; Li Y; Xu J; Li Z; Lu W; Su X; Zou W; Jin M; Chen H; Fang L
    Antiviral Res; 2011 Dec; 92(3):493-6. PubMed ID: 22020305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.